PDC*line Pharma has been selected for both a poster and short talk presentation at the CIMT 2024 annual meeting!

We are delighted to announce that we have been selected for both a poster and short talk presentation at the CIMT 2024 annual meeting! 

The short talk has been made by Sebastien Michel May 16th in Mainz, Germany.  

Title of the poster is: "Evaluation of the immune response using TCR repertoire analysis in patients with non-small cell lung cancer treated with a PDC*line cell-based cancer vaccine in combination or not with an anti-PD-1".

Poster is available at the link here: /sites/default/files/documents/Smichel_CIMT2024.pdf

About CIMT

CIMT is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. Since the Association was founded, hundreds of scientific papers have documented the discoveries and advancements in cancer immunology.

More information about this meeting is available here: www.meeting.cimt.eu